Tobramycin Serum Concentrations in Tracheostomy-Dependent Children Receiving Inhaled Tobramycin
dc.contributor.author | Hughes, Kaitlin M. | |
dc.contributor.author | Cristea, A. Ioana | |
dc.contributor.author | Tillman, Emma M. | |
dc.contributor.department | Medicine, School of Medicine | en_US |
dc.date.accessioned | 2021-09-02T19:00:39Z | |
dc.date.available | 2021-09-02T19:00:39Z | |
dc.date.issued | 2020-06 | |
dc.description.abstract | Introduction: In recent years, administration of inhaled aminoglycosides has gained popularity in tracheostomy-dependent pediatric patients because of medication delivery to the target site of action while minimizing systemic absorption and adverse effects. A recent report of detectable serum tobramycin concentrations in critically ill children receiving inhaled tobramycin 300 mg every 12 h prompted our investigation in tracheostomy-dependent pediatric patients receiving inhaled tobramycin 80 mg every 8 h. Methods: Serum tobramycin trough concentrations were obtained from tracheostomy-dependent pediatric patients receiving treatment with inhaled tobramycin 80 mg every 8 h for the treatment of tracheitis. Patient data, including demographic data, medical history, renal function, and serum concentrations, were collected. Results: Twelve patients with a median age of 0.5 (0.3–6.1) years had serum tobramycin concentrations evaluated. Eleven of the 12 patients had undetectable trough concentrations (<0.6 mcg/mL). All of these patients had normal blood urea nitrogen (BUN) and serum creatinine (SCr) for age and no history of kidney disease. One patient had a detectable trough concentration of 2.1 mcg/mL. This patient was 11 months old and had polycystic kidney disease with an elevated BUN and SCr for age. Conclusions: Detectable serum concentration from systemic absorption of inhaled tobramycin 80 mg every 8 h is unlikely in tracheostomy-dependent pediatric patients with normal renal function. However, in tracheostomy-dependent pediatric patients with a history of renal dysfunction or elevations in BUN or SCr, inhaled tobramycin should be used with caution. Monitoring serum concentrations to guide dose modification should be considered in these patients. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Hughes, K. M., Cristea, A. I., & Tillman, E. M. (2020). Tobramycin Serum Concentrations in Tracheostomy-Dependent Children Receiving Inhaled Tobramycin. Pediatric Allergy, Immunology, and Pulmonology, 33(2), 92–95. https://doi.org/10.1089/ped.2020.1161 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/26578 | |
dc.language.iso | en | en_US |
dc.publisher | Liebert | en_US |
dc.relation.isversionof | 10.1089/ped.2020.1161 | en_US |
dc.relation.journal | Pediatric Allergy, Immunology, and Pulmonology | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | Author | en_US |
dc.subject | inhaled aminoglycosides | en_US |
dc.subject | tracheostomy-dependent pediatric patients | en_US |
dc.subject | tobramycin | en_US |
dc.title | Tobramycin Serum Concentrations in Tracheostomy-Dependent Children Receiving Inhaled Tobramycin | en_US |
dc.type | Article | en_US |